Phosphorex Names Jerry Williamson as CEO

Phosphorex, a drug delivery-focused CDMO and an Ampersand Capital Partners portfolio company, has appointed Jerry Williamson as Chief Executive Officer. With over 35 years of leadership experience in bioscience and diagnostics, Williamson brings a track record of building innovative life sciences companies and delivering strong commercial and operational outcomes.

“We’re thrilled to welcome Jerry to the Phosphorex team,” said Trevor Wahlbrink, General Partner at Ampersand. “His exceptional leadership experience, particularly in scaling services platforms offering science-driven solutions, makes him ideally suited to lead Phosphorex through its next phase of innovation and expansion.”

Experience

Most recently, Williamson served as CEO of Sengenics, where he led the company’s strategic transformation in immunology profiling. He previously held CEO roles at NanoView Biosciences, KEW Inc., and Metamark Genetics, and served as president of Genetix LLC, Biacore Inc. and Pyrosequencing Inc. His expertise spans research tools, diagnostics, and analytical technologies—sectors that align strongly with Phosphorex’s strategic growth ambitions.

“I’m excited to join Phosphorex and lead a team that’s at the forefront of enabling drug delivery innovation,” said Williamson. “The company has built an impressive foundation in lipid-based technologies, and I look forward to accelerating our growth and impact in partnership with our customers and investors.”